Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. Our mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. We are discovering and developing innovative therapies that target key drivers of chronic inflammatory diseases.
| Website | http://www.evommune.com |
| Revenue | $8.4 million |
| Employees | 69 (45 on RocketReach) |
| Founded | 2020 |
| Industry | Biotechnology Research |
| Keywords | Inflammation, Immunology, Biotechnology, Autoimmune Diseases, Therapeutics, Immunomodulation, Drug Development, Biopharma, New Therapies, Pharmaceutical, Clinical Trials, Treatment, Rare Diseases, Research, Patient Care, Scientific Research, Medicine, Health |
| Competitors | Allergenis, AstraZeneca, ImmunoTek Bio Centers, LLC, Regeneron, Sanofi, Zymergen, Inc., Maven Bio, CSL Behring, Grifols +38 more (view full list) |
Looking for a particular Evommune employee's phone or email?
The Evommune annual revenue was $8.4 million in 2026.
Luis Pena is the Founder, President and CEO of Evommune.
45 people are employed at Evommune.